^
Association details:
| Biomarker: | MYC negative |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
212 - Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial
Published date:
01/13/2021
Excerpt:
BL Myc− (n=38/111) was associated with improved outcomes vs Myc+ (n=73/111), including longer median DOR (NR vs 19mo [95%CI, 3.4-NE]), PFS (6.2mo [95%CI, 2.9-NE] vs 2.5mo [95%CI, 1.7-3.0]; Fig1A), and OS (21mo [95%CI, 10-NE] vs 7.8mo [95%CI, 4.6-18]).
Trial ID:
Source:
Title:
1194 Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
Published date:
11/04/2020
Excerpt:
Of 111 pts whose baseline archival tumor biopsies were tested for baseline Myc expression, 73 were Myc+ and 38 were Myc−. Baseline Myc− status was associated with improved outcomes compared with Myc+ pts, including longer median DOR (not reached vs 19 months [95% CI, 3.4-NE]), PFS (6.2 months [95% CI, 2.9-NE] vs 2.5 months [95% CI, 1.7-3.0]; Fig.1A), and OS (21 months [95% CI, 10-NE] vs 7.8 months [95% CI, 4.6-18])...
Trial ID:
